Across TCGA pan-cancer cohorts, S100A7L2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated S100A7L2 data layer compared with 10 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher S100A7L2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated S100A7L2 expression acts as an unfavorable survival marker.

OV and SARC are the cancer types where S100A7L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.142	0.541	.002	12	view →
SARC	DFS	Median	All	0.038	0.611	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: S100A7L2 tumor-vs-normal RNA expression · all S100A7L2 data types